To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Katherine M Malinda, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4140, MSC 7814, Bethesda, MD 20892, 301–435–0912, katherine_malinda@csr.nih.gov.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group Molecular Genetics A Study Section.

Date: June 25, 2012.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Michael M Sveda, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1114, MSC 7890, Bethesda, MD 20892, 301–435–3565, svedam@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Member
Conflict: Epidemiology.

Date: June 25–26, 2012.

Time: 9:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Denise Wiesch, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3150, MSC 7770, Bethesda, MD 20892, (301) 435–0684, wieschd@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel PAR Panel: Biodemography of Aging.

Date: June 26–27, 2012.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Aftab A Ansari, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892, 301–435–1169, greenwep@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Translational Research in Diabetes, Obesity and Endocrine Disorders.

Date: June 27, 2012.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Michael M Sveda, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, 301–237–9931, ansaria@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Translational Research in Diabetes, Obesity and Endocrine Disorders.

Date: June 27, 2012.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Aftab A Ansari, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892, 301–435–1169, greenwep@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Translational Research in Diabetes, Obesity and Endocrine Disorders.

Date: June 27, 2012.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Michael M Sveda, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, 301–237–9931, ansaria@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Translational Research in Diabetes, Obesity and Endocrine Disorders.

Date: June 27, 2012.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Alexander Gubin, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4196, MSC 7812, Bethesda, MD 20892, 301–435–2902, gubin@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Skeletal Muscle Biology, Physiology and Disease.

Date: June 26, 2012.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Eileen W Bradley, DSC, Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5100, MSC 7854, Bethesda, MD 20892, (301) 435–1179, bradleye@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Clinical and Translational Imaging Applications.

Date: June 27, 2012.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Alexander Gubin, Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4196, MSC 7812, Bethesda, MD 20892, 301–435–2902, gubin@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Skeletal Muscle Biology, Physiology and Disease.

Date: June 26, 2012.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.

This notice is also available on the
Internet at http://www.workplace.
samhsa.gov and http://www.drugfree
workplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION:
The Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The “Mandatory
Guidelines for Federal Workplace Drug
Testing Programs”, as amended in the
revisions listed above, requires strict
standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.

To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.

Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.

In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:

Instrumented Initial Testing Facilities
(IITF)

None.

Laboratories

ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016, (Formerly:
Bayshore Clinical Laboratory).

ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,

Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150.

Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)

Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)

Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23269, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)

Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).

Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.

Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
23236, 804–378–9130, (Formerly:
Centinela

DrugScan, Inc., P.O. Box 2969, 1119
Mears Road, Warminster, PA 18974,

EHSOLY Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.

Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.

Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.

Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)

Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6000/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).

Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 686–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center).

LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)

Maxxam Analytics,* 6740 Campobello
Road, Mississauga, ON, Canada L5N
2L8, 905–817–5700, (Formerly:
Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)

MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,

MetroLab-Legacy Laboratory Services,
1225 NE. 2nd Ave., Portland, OR

Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088.

National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield,

One Source Toxicology Laboratory,
Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888–747–3774, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory).

Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory).

Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/800–
541–7891x7.

Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121, 858–643–
5555.

Quest Diagnostics Incorporated, 5601
Office Blvd., Albuquerque, NM 87109,
505–727–6300/800–999–5227,
(Formerly: S.E.D. Medical
Laboratories).

Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-
Science Laboratories).

Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370, (Formerly: SmithKline
Beecham Clinical Laboratories).

South Bend Medical Foundation,
Inc., 530 N. Lafayette Blvd., South Bend,
IN 46601, 574–234–4176 x1276.

Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027.
SUMMARY: The Department of Homeland Security (DHS) announced the establishment of the Critical Infrastructure Partnership Advisory Council (CIPAC) by notice published in the Federal Register on March 24, 2006. This committee was exempted from the Federal Advisory Committee Act (FACA) under the authority of the Secretary of the Department of Homeland Security in section 871 of the Homeland Security Act of 2002, 6 U.S.C. 451(a); that notice identified the purpose of CIPAC as well as its membership. This notice provides (1) that the Secretary has determined that CIPAC and its exemption from FACA continues to serve the purpose for which it was established and has renewed its charter, which is required every two years; (2) instructions on how the public can obtain the CIPAC membership roster and other information on the Council; and (3) information on the membership within CIPAC of the members of the State, Local, Tribal, and Territorial Government Coordinating Council (SLTTGCC).

FOR FURTHER INFORMATION CONTACT: Larry May, Designated Federal Officer, Critical Infrastructure Partnership Advisory Council, Department of Homeland Security, National Protection and Programs Directorate, 245 Murray Lane, Mail Stop 0607, Arlington, VA 20598–0607.

SUPPLEMENTARY INFORMATION: Notice of CIPAC Renewal: The Secretary of Homeland Security extended the CIPAC charter on March 19, 2012, for a period of two years. The current CIPAC charter reflecting the Secretary’s action is available on the CIPAC Web site (http://www.dhs.gov/cipac).

Purpose and Activities: CIPAC facilitates interaction between government officials and representatives of the community of owners and operators for each of the critical infrastructure sectors defined by Homeland Security Presidential Directive 7 (HSPD–7) and identified in the National Infrastructure Protection Plan. The scope of activities covered by CIPAC includes planning; coordinating among government and critical infrastructure owner/operator security partners; implementing security program initiatives; conducting operational activities related to critical infrastructure protection security measures, incident response, recovery, infrastructure resilience; reconstituting critical infrastructure assets and systems for both man-made and naturally occurring events; and sharing threat, vulnerability, risk mitigation, and infrastructure continuity information. Organizational Structure: CIPAC members are organized into the eighteen HSPD–7 critical infrastructure sectors. A Sector Coordinating Council (SCC) generally exists within each sector containing critical infrastructure owner/operators. The SCC includes these critical infrastructure owners/operators or their representative trade associations. Each sector also has a Government Coordinating Council (GCC) whose membership includes a lead Federal agency, defined as the Sector Specific Agency, and all relevant Federal, state, local, tribal, and/or territorial government agencies (or their representative bodies) whose mission interests also involve the scope of the CIPAC activities for that particular sector.

Membership: CIPAC membership includes: (1) Critical infrastructure owner/operator members of an SCC; (2) trade association members of an SCC representing the interests of critical infrastructure owners/operators; (3) each sector’s GCC; and (4) governmental officials who are part of DHS’s SLTTGCC. The new charter also prohibits Federally registered lobbyists from representing SCC members at CIPAC meetings. This requirement complies with a Presidential Policy Memorandum, “Lobbyists on Agency Boards and Commissions,” issued on June 18, 2010.

CIPAC Membership Roster and Council Information: The current roster of CIPAC membership is published on the CIPAC Web site (http://www.dhs.gov/cipac) and is updated as CIPAC membership changes. Members of the public may visit the CIPAC Web site at any time to obtain current CIPAC membership as well as the current and historic list of CIPAC meetings and agendas. Dated: May 22, 2012.

Larry May,
Designated Federal Officer for the CIPAC.

[FR Doc. 2012–13234 Filed 5–31–12; 8:45 am]
BILLING CODE 9110–9P–P